Screening of key miRNAs and evaluation of their diagnostic and prognostic values in nasopharyngeal carcinoma

Zhuo,Xianlu; Zhou,Wei; Ye,Huiping; Li,Dairong; Chang,Aoshuang; Wu,Yongzhong; Zhou,Qi

doi:10.3892/ol.2019.10231

Screening of key miRNAs and evaluation of their diagnostic and prognostic values in nasopharyngeal carcinoma

Authors:
- Xianlu Zhuo
- Wei Zhou
- Huiping Ye
- Dairong Li
- Aoshuang Chang
- Yongzhong Wu
- Qi Zhou
View Affiliations

Affiliations: Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing 400030, P.R. China, Department of Otorhinolaryngology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China
Published online on: April 9, 2019 https://doi.org/10.3892/ol.2019.10231
Pages: 5803-5810

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing evidence has revealed the importance of microRNA (miRNA/miR) in cancer genesis and progression. The aim of the current study was to identify the key miRNAs involved in the onset and development of nasopharyngeal carcinoma (NPC) and to further evaluate their diagnostic and prognostic values. Microarray data were obtained and analyzed to screen differentially expressed miRNAs (DEMs) between patients with NPC and healthy controls. The target genes of the DEMs were predicted and their possible functions were evaluated. The diagnostic and prognostic values of the DEMs were subsequently investigated. A total of 4 DEMs, including miR‑18a, miR‑135b, miR‑204 and miR‑497, were identified. Gene Ontology (GO) and pathway enrichment analysis revealed that the target genes were enriched in a number of GO terms and signaling pathways. The results demonstrated that the selected DEMs may present potential diagnostic factors for NPC. In addition, miR‑18a [Hazard ratio (HR), 3.405; 95% confidence interval (CI), 1.334‑8.693] and miR‑135b (HR, 2.482; 95% CI, 1.014‑6.076) may serve prognostic roles for patients with NPC. In summary, the present study identified 4 miRNAs that may be involved in the genesis and development of NPC. In addition, miR‑18a and miR‑135b may present useful prognostic markers for patients with NPC. Future in vitro and in vivo investigations are warranted to substantiate the results obtained in the current study.

View Figures

View References

1	Perri F, Della Vittoria Scarpati G, Caponigro F, Ionna F, Longo F, Buonopane S, Muto P, Di Marzo M, Pisconti S and Solla R: Management of recurrent nasopharyngeal carcinoma: Current perspectives. Onco Targets Ther. 12:1583–1591. 2019. View Article : Google Scholar : PubMed/NCBI
2	He Y, Guo T, Guan H, Wang J, Sun Y and Peng X: Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A meta-analysis. Cancer Manag Res. 10:1419–1428. 2018. View Article : Google Scholar : PubMed/NCBI
3	Wang L, Guo Y, Xu J, Chen Z, Jiang X, Zhang L, Huang S, He X and Zhang Y: Clinical analysis of recurrence patterns in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. Ann Otol Rhinol Laryngol. 126:789–797. 2017. View Article : Google Scholar : PubMed/NCBI
4	Cheng JZ, Chen JJ, Xue K, Wang ZG and Yu D: Clinicopathologic and prognostic significance of VEGF, JAK2 and STAT3 in patients with nasopharyngeal carcinoma. Cancer Cell Int. 18:1102018. View Article : Google Scholar : PubMed/NCBI
5	Liu J, Tang G, Huang H, Li H, Zhang P and Xu L: Expression level of NUAK1 in human nasopharyngeal carcinoma and its prognostic significance. Eur Arch Otorhinolaryngol. 275:2563–2573. 2018. View Article : Google Scholar : PubMed/NCBI
6	Tang J, Zhong G, Wu J, Chen H and Jia Y: SOX2 recruits KLF4 to regulate nasopharyngeal carcinoma proliferation via PI3K/AKT signaling. Oncogenesis. 7:612018. View Article : Google Scholar : PubMed/NCBI
7	Dragomir M, Mafra ACP, Dias SMG, Vasilescu C and Calin GA: Using microRNA networks to understand cancer. Int J Mol Sci. 19:E18712018. View Article : Google Scholar : PubMed/NCBI
8	Cheng JZ, Chen JJ, Wang ZG and Yu D: MicroRNA-185 inhibits cell proliferation while promoting apoptosis and autophagy through negative regulation of TGF-β1/mTOR axis and HOXC6 in nasopharyngeal carcinoma. Cancer Biomark. 23:107–123. 2018. View Article : Google Scholar : PubMed/NCBI
9	Zhao X and Chu J: MicroRNA-379 suppresses cell proliferation, migration and invasion in nasopharyngeal carcinoma by targeting tumor protein D52. Exp Ther Med. 16:1232–1240. 2018.PubMed/NCBI
10	Yu JW, Mai W, Cui YL and Kong LY: Genes and pathways identified in thyroid carcinoma based on bioinformatics analysis. Neoplasma. 63:559–568. 2016. View Article : Google Scholar : PubMed/NCBI
11	Tokar T, Pastrello C, Rossos AEM, Abovsky M, Hauschild AC, Tsay M, Lu R and Jurisica I: mirDIP 4.1-integrative database of human microRNA target predictions. Nucleic Acids Res. 46:D360–D370. 2018. View Article : Google Scholar : PubMed/NCBI
12	Al-Mubaid H: Gene multifunctionality scoring using gene ontology. J Bioinform Comput Biol. 16:18400182018. View Article : Google Scholar : PubMed/NCBI
13	Kanehisa M, Furumichi M, Tanabe M, Sato Y and Morishima K: KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 45:D353–D361. 2017. View Article : Google Scholar : PubMed/NCBI
14	Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, Kong L, Gao G, Li CY and Wei L: KOBAS 2.0: A web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. 39:W316–W322. 2011. View Article : Google Scholar : PubMed/NCBI
15	Plieskatt JL, Rinaldi G, Feng Y, Levine PH, Easley S, Martinez E, Hashmi S, Sadeghi N, Brindley PJ, Bethony JM and Mulvenna JP: Methods and matrices: Approaches to identifying miRNAs for nasopharyngeal carcinoma. J Transl Med. 12:32014. View Article : Google Scholar : PubMed/NCBI
16	Lee KT, Tan JK, Lam AK and Gan SY: MicroRNAs serving as potential biomarkers and therapeutic targets in nasopharyngeal carcinoma: A critical review. Crit Rev Oncol Hematol. 103:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
17	Liang C, Zhang X, Wang HM, Liu XM, Zhang XJ, Zheng B, Qian GR and Ma ZL: MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer. Cell Death Dis. 8:e27642017. View Article : Google Scholar : PubMed/NCBI
18	Xu X, Zhu S, Tao Z and Ye S: High circulating miR-18a, miR-20a, and miR-92a expression correlates with poor prognosis in patients with non-small cell lung cancer. Cancer Med. 7:21–31. 2018. View Article : Google Scholar : PubMed/NCBI
19	Liang Q, Zhang G, Wang J and Sheng S: Diagnostic value of MicroRNA-18a for gastric cancer: A meta-analysis. Clin Lab. 64:177–184. 2018. View Article : Google Scholar : PubMed/NCBI
20	Liu P, Qi X, Bian C, Yang F, Lin X, Zhou S, Xie C, Zhao X and Yi T: MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK. Oncol Lett. 13:4039–4046. 2017. View Article : Google Scholar : PubMed/NCBI
21	Lu M, Huang Y, Sun W, Li P and Li L: miR-135b-5p promotes gastric cancer progression by targeting CMTM3. Int J Oncol. 52:589–598. 2018.PubMed/NCBI
22	Zhang Z, Che X, Yang N, Bai Z, Wu Y, Zhao L and Pei H: miR-135b-5p promotes migration, invasion and EMT of pancreatic cancer cells by targeting NR3C2. Biomed Pharmacother. 96:1341–1348. 2017. View Article : Google Scholar : PubMed/NCBI
23	Palkina N, Komina A, Aksenenko M, Moshev A, Savchenko A and Ruksha T: miR-204-5p and miR-3065-5p exert antitumor effects on melanoma cells. Oncol Lett. 15:8269–8280. 2018.PubMed/NCBI
24	Shuai F, Wang B and Dong S: microRNA-204 inhibits the growth and motility of colorectal cancer cells by downregulation of CXCL8. Oncol Res. 15:8269–8280. 2018.
25	Qu F, Ye J, Pan X, Wang J, Gan S, Chu C, Chu J, Zhang X, Liu M, He H and Cui X: MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma. J Drug Target. 27:1–15. 2018.PubMed/NCBI
26	Cheng H, Dong H, Feng J, Tian H, Zhang H and Xu L: miR-497 inhibited proliferation, migration and invasion of thyroid papillary carcinoma cells by negatively regulating YAP1 expression. Onco Targets Ther. 11:4711–4721. 2018. View Article : Google Scholar : PubMed/NCBI
27	Feng Y, Cao C, Hu Q and Chen X: Prognostic value and staging classification of lymph nodal necrosis in nasopharyngeal carcinoma after intensity-modulated radiotherapy. Cancer Res Treat. 2018. View Article : Google Scholar